Related Experiment Video

Updated: Aug 16, 2026

Spectrophotometric Methods for the Study of Eukaryotic Glycogen Metabolism
07:59

Spectrophotometric Methods for the Study of Eukaryotic Glycogen Metabolism

Published on: August 19, 2021

Biochemical characteristics and increased tetraglucoside excretion in patients with phosphorylase kinase deficiency

E Morava1, S B Wortmann, H Zweers van Essen

  • 1Department of Pediatrics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. E.Morava@cukz.umcn.nl

Journal of Inherited Metabolic Disease
|September 10, 2005
PubMed

Insights

Glycogen storage disease type IXa can cause infantile hepatomegaly and growth issues. Increased urinary tetraglucoside and high cholesterol may indicate this rare genetic disorder.

Area of Science:

  • Biochemistry
  • Genetics
  • Pediatrics

Background:

  • Glycogen storage disease type IXa (GSD IXa) presents with infantile hepatomegaly, distinct growth patterns, and variable blood biochemical changes.
  • Clinical manifestations and biochemical profiles in GSD IXa patients require further elucidation.

Purpose of the Study:

  • To investigate the clinical and biochemical characteristics of GSD IXa in seven unrelated children.
  • To explore the correlation between urinary oligosaccharide excretion, lipid profiles, and GSD IXa.

Main Methods:

  • Clinical evaluation of seven children with suspected GSD IXa.
  • Biochemical analysis including urinary oligosaccharide excretion and serum lipid levels (cholesterol, triglycerides).

Main Results:

  • Increased urinary tetraglucoside excretion was observed in four of the seven patients.
  • Three patients with elevated tetraglucoside also exhibited persistently high cholesterol and triglyceride concentrations.
  • These findings suggest a potential link between specific urinary markers and metabolic dysregulation in GSD IXa.

Conclusions:

  • Screening for urinary tetraglucoside excretion and measuring serum cholesterol are proposed as valuable tools for assessing potential glycogenosis in children with growth delay and/or hepatomegaly.
  • Early detection through these biochemical markers can aid in the diagnosis and management of GSD IXa.

More Related Videos

Radiochemical Assessment of Glycogen Synthase Enzyme Activity in Animal Tissue02:30

Radiochemical Assessment of Glycogen Synthase Enzyme Activity in Animal Tissue

Published on: October 24, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...